Targeting cell division protein CDK2 could boost immunotherapy response across a wide range of cancers

New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.

Read it at Medical Xpress ↗

← Front page